Patents by Inventor Gudrun Schappacher

Gudrun Schappacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240127961
    Abstract: A method for determining a next hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosage for a first patient using a patient HIF-PHI model is provided. The method includes obtaining population patient data indicating HIF-PHI dosages and hemoglobin measurements for the patients. Then, virtual patient avatars are generated based on the population patient data. Each of the virtual patient avatars indicates a set of personalized model parameters for a HIF-PHI model. A plurality of HIF-PHI models are determined for the virtual patient avatars. Using the HIF-PHI models, one or more HIF-PHI treatment schemes for administering the HIF-PHI dosages is determined. Subsequently, the HIF-PHI treatment schemes along with a hematocrit and/or hemoglobin concentration for a patient are used to determine a next HIF-PHI dosage for the patient, and the next HIF-PHI dosage is administered for the patient.
    Type: Application
    Filed: October 5, 2022
    Publication date: April 18, 2024
    Inventors: Doris Fuertinger, David Joerg, Gudrun Schappacher-Tilp, Peter Kotanko
  • Publication number: 20240127962
    Abstract: A computing system for determining a systematic training strategy for the user is provided. The computing system includes a user device that uses one or more sensors to obtain partial pressure of oxygen (PO2) levels of a user over a period of time. The user device provides previous PO2 levels to a personalized erythropoiesis model generation computing platform. The computing platform obtains individualized user data for the user indicating or more previous hematocrit and/or hemoglobin measurements for the user. The computing platform determines an individualized erythropoiesis model for the user based on the one or more previous hematocrit and/or hemoglobin measurements and the previous PO2 information, and employs the individualized erythropoiesis model to determine predicted hematocrit and/or hemoglobin measurements. The computing platform performs one or more actions based on the one or more predicted hematocrit and/or hemoglobin measurements.
    Type: Application
    Filed: October 5, 2022
    Publication date: April 18, 2024
    Inventors: Peter Kotanko, Ulrike Kotanko, Sabrina Casper, David Joerg, Gudrun Schappacher-Tilp, Doris Fuertinger
  • Publication number: 20230106535
    Abstract: The described technology may include processes to model parathyroid gland (PTG) functionality and/or calcimimetic administration to healthy subjects and/or patients with a health abnormality that affects PTG function. In one embodiments, a computer-implemented method of calcimimetic analysis of PTG functionality may include accessing a calcimimetic model configured to simulate a functionality of a PTG of at least one patient, the calcimimetic model comprising at least one of a pharmacokinetic model or a pharmacodynamic model, providing a calcimimetic administration of a calcimimetic to the at least one patient via the calcimimetic model according to an administration process, and determining calcimimetic information based on the calcimimetic administration via the calcimimetic model for the at least one patient, the calcimimetic information configured to indicate an efficacy of the calcimimetic administration. Other embodiments are described.
    Type: Application
    Filed: October 1, 2021
    Publication date: April 6, 2023
    Inventors: Gudrun Schappacher-Tilp, Peter Kotanko
  • Patent number: 11450405
    Abstract: The described technology may include processes to model parathyroid gland (PTG) functionality and/or calcimimetic administration to patients with a health abnormality that affects PTG function. In one embodiment, a method may include providing a PTG functionality model configured to simulate functionality of a PTG of a patient with a health abnormality affecting PTG function, the model may receive a parameters configured to regulate activity of calcium-sensing receptors (CaSR), the parameters may include a calcium concentration, a vitamin D concentration, and a phosphorous concentration, simulate CaSR expression and vitamin D receptor (VDR) expression via a positive feedback loop between the CaSR expression and the VDR expression, and suppression of the CaSR expression and the VDR expression by P, initiate at least one PTG adaptation based on the parameters, and determine a model output comprising a parathyroid hormone (PTH) concentration at one or more time intervals. Other embodiments are described.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: September 20, 2022
    Assignees: Fresenius Medical Care Holdings, Inc., FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Gudrun Schappacher-Tilp, Peter Kotanko, Doris Helen Fuertinger
  • Publication number: 20200126632
    Abstract: The described technology may include processes to model parathyroid gland (PTG) functionality and/or calcimimetic administration to patients with a health abnormality that affects PTG function. In one embodiment, a method may include providing a PTG functionality model configured to simulate functionality of a PTG of a patient with a health abnormality affecting PTG function, the model may receive a parameters configured to regulate activity of calcium-sensing receptors (CaSR), the parameters may include a calcium concentration, a vitamin D concentration, and a phosphorous concentration, simulate CaSR expression and vitamin D receptor (VDR) expression via a positive feedback loop between the CaSR expression and the VDR expression, and suppression of the CaSR expression and the VDR expression by P, initiate at least one PTG adaptation based on the parameters, and determine a model output comprising a parathyroid hormone (PTH) concentration at one or more time intervals. Other embodiments are described.
    Type: Application
    Filed: October 17, 2019
    Publication date: April 23, 2020
    Inventors: Gudrun Schappacher-Tilp, Peter Kotanko, Doris Helen Fuertinger
  • Patent number: 7839502
    Abstract: Methods for wavelength calibration of spectrometers are provided which achieve better calibration accuracies than conventional peak search methods. The methods are based on the principle of a stepwise relative shift of corresponding measured-value blocks of a model and calibration spectrum where a correlation value is calculated for each shift step. A shift value is determined for each measured-value block at which the correlation value reaches an optimum. A value pair consisting of a position marker of the measured-value block and the associated shift value is determined for each measured-value block. These value pairs represent the design points for fitting to a suitable assignment function. Coefficients obtained in this manner can be used directly as coefficients of a wavelength assignment or be combined with the coefficients of an existing first wavelength assignment in that they for example replace or are offset against the coefficients of an existing first wavelength assignment.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: November 23, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Rene Lukas, Gudrun Schappacher
  • Publication number: 20080297796
    Abstract: The invention concerns methods for the wavelength calibration of spectrometers and in particular secondary spectrometers which achieve considerably better calibration accuracies than the conventional peak search methods especially for spectrometers with a relatively large bandwidth. The methods according to the invention are based on the principle of a stepwise relative shift of corresponding measured-value blocks of a model and calibration spectrum where a correlation value is calculated for each shift step. A shift value is determined for each measured-value block at which the correlation value reaches an optimum. A value pair consisting of a position marker of the measured-value block and the associated shift value is determined for each measured-value block. These value pairs represent the design points for fitting to a suitable assignment function.
    Type: Application
    Filed: May 22, 2008
    Publication date: December 4, 2008
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Rene Lukas, Gudrun Schappacher